Thyroid eye disease
Conditions
Brief summary
The primary study endpoint will assess the rate at which safety events occur after starting treatment with VRDN-003 (Treatment Emergent Adverse Event) through Week 24.
Detailed description
Changes in eye bulging at Week 24 versus measurements before the first dose., The rate at which safety events occur after starting treatment with VRDN-003 through Week 52.
Interventions
Sponsors
Viridian Therapeutics Inc.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary study endpoint will assess the rate at which safety events occur after starting treatment with VRDN-003 (Treatment Emergent Adverse Event) through Week 24. | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in eye bulging at Week 24 versus measurements before the first dose., The rate at which safety events occur after starting treatment with VRDN-003 through Week 52. | — |
Countries
France, Germany, Poland, Spain
Outcome results
None listed